Number of pregnancies and ovariectomy modify mammary carcinoma development in transgenic HER-2/neu female mice

被引:6
作者
Anisimov, VN
Popovich, IG
Alimova, IN
Zabezhinski, MA
Semenchenko, AV
Yashin, AI
机构
[1] NN Petrov Oncol Res Inst, Dept Carcinogenesis & Oncogerontol, St Petersburg 197758, Russia
[2] Max Planck Inst Demog Res, D-18057 Rostock, Germany
基金
俄罗斯基础研究基金会;
关键词
HER-2/neu transgenic mice; pregnancy; ovariectomy; mammary carcinoma; BREAST-CANCER RISK; NEU/ERBB-2; ONCOGENE; TRANSIENT INCREASE; MOUSE MODEL; EXPRESSION; TUMORS; NEU; DIFFERENTIATION; OVEREXPRESSION; AMPLIFICATION;
D O I
10.1016/S0304-3835(02)00721-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We studied effect of pregnancy and ovariectomy on the development of mammary tumors in homozygous female HER-2/neutransgenic mice. The mean life span of uniparous mice was decreased by 16% in comparison to the control (P < 0.05) and of mice which have two pregnancies decreased by 11% (P < 0.05). Ovariectomy at the age of 2 months was followed by 32.7% increase in mean life span of mice. The incidence or multiplicity of mammary adenocarcinomas did not change in uniparous mice, whereas the size of the tumors and metastatic potential were decreased as compared to the virgins. When mice have two full-time pregnancies, there was an increase in multiplicity of mammary carcinomas and significant (2.1-fold) decrease in the survival time of tumor-bearing mice. Ovariectomy significantly decreased the total incidence of mammary carcinomas, the number of tumors. per tumor-bearing animal, and inhibited metastasizing into lungs. Our results indicate that pregnancy accelerated the development of mammary adenocarcinomas in transgenic HER-2/neu mice whereas ovariectomy inhibits their development. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:49 / 55
页数:7
相关论文
共 30 条
[1]   Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis [J].
Andrechek, ER ;
Hardy, WR ;
Siegel, PM ;
Rudnicki, MA ;
Cardiff, RD ;
Muller, WJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (07) :3444-3449
[2]   Inhibitory effect of the peptide epitalon on the development of spontaneous mammary tumors in HER-2/neu transgenic mice [J].
Anisimov, VN ;
Khavinson, VKH ;
Provinciali, M ;
Alimova, IN ;
Baturin, DA ;
Popovich, IG ;
Zabezhinski, MA ;
Imyanitov, EN ;
Mancini, R ;
Franceschi, C .
INTERNATIONAL JOURNAL OF CANCER, 2002, 101 (01) :7-10
[3]  
*APT SYST INC, 1994, GAUSS SYST GRAPH MAN
[4]  
Blanchard D K, 2000, Clin Breast Cancer, V1, P127
[5]   The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting [J].
Cardiff, RD ;
Anver, MR ;
Gusterson, BA ;
Hennighausen, L ;
Jensen, RA ;
Merino, MJ ;
Rehm, S ;
Russo, J ;
Tavassoli, FA ;
Wakefield, LM ;
Ward, JM ;
Green, JE .
ONCOGENE, 2000, 19 (08) :968-988
[6]   Oncogenic activating mutations in the neu/erbB-2 oncogene are involved in the induction of mammary tumors [J].
Chan, R ;
Muller, WJ ;
Siegel, PM .
CANCER PREVENTION: NOVEL NUTRIENT AND PHARMACEUTICAL DEVELOPMENTS, 1999, 889 :45-51
[7]   MOUSE MAMMARY-TUMOR VIRUS ACTIVATES FGF-3/INT-2 LESS FREQUENTLY IN TUMORS FROM VIRGIN THAN FROM PAROUS MICE [J].
CLAUSSE, N ;
SMITH, R ;
CALBERGBACQ, CM ;
PETERS, G ;
DICKSON, C .
INTERNATIONAL JOURNAL OF CANCER, 1993, 55 (01) :157-163
[8]  
Cox D.R., 1996, Analysis of Survival Data
[9]   Persistent parity-induced changes in growth factors, TGF-β3, and differentiation in the rodent mammary gland [J].
D'Cruz, CM ;
Moody, SE ;
Master, SR ;
Hartman, JL ;
Keiper, EA ;
Imielinski, MB ;
Cox, JD ;
Wang, JY ;
Ha, SI ;
Keister, BA ;
Chodosh, LA .
MOLECULAR ENDOCRINOLOGY, 2002, 16 (09) :2034-2051